A Phase 1b/2 Safety and Tolerability study of MEDI6469 in Combination with Therapeutic Immune Agents or Monoclonal Antibodies - MEDI6469

Study identifier:D4981C00001

ClinicalTrials.gov identifier:NCT02205333

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination with Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects with Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas

Medical condition

Advanced Solid Tumors

Phase

Phase 1/2

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

48

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 13 Aug 2014
Primary Completion Date: 08 Apr 2016
Study Completion Date: 08 Apr 2016

Study design

Allocation: Non-randomized
Endpoint Classification: Safety
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2017 by MedImmune, LLC

Sponsors

MedImmune, LLC

Collaborators

-

Inclusion and exclusion criteria